Angiotensin Receptor Antagonists: all 1,100 studies that test it

Page 11 of 11. Open to participants first (75), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis CCompletedNCT00265642Phase 3
• Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate HypertensionCompletedNCT00263003Phase 3
• Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential HypertensionCompletedNCT00257491Phase 3
• A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and HypercholesterolemiaCompletedNCT00254475Phase 3
• A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.CompletedNCT00250562Phase 3
• Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma ActivitiesCompletedNCT00242814Phase 4
• High Doses of Candesartan Cilexetil on the Reduction of ProteinuriaCompletedNCT00242346Phase 3
• Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic SyndromeCompletedNCT00241150Phase 4
• A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 MgCompletedNCT00241137Phase 3
• Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With DiabetesCompletedNCT00241124Phase 4
• The VALIDATE Study of Valsartan for Patients With Early Stage Heart FailureCompletedNCT00241098Phase 4
• Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes MellitusCompletedNCT00241085Phase 4
• Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose ToleranceCompletedNCT00241072Phase 4
• A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With HypertensionCompletedNCT00241007Phase 3
• A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)CompletedNCT00240474Phase 4
• A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II PatientsCompletedNCT00240448Phase 4
• Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 DiabetesCompletedNCT00240422Phase 4
• Prevention of Decompensation in Liver CirrhosisStatus unknownNCT00239096Phase 4
• Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney DiseaseStatus unknownNCT00235287Phase 4
• Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)CompletedNCT00234858Phase 4
• TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention TrialCompletedNCT00227318Phase 3
• Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent PacemakersStatus unknownNCT00225667Phase 3
• PHARES Study: Management of Resistant HypertensionCompletedNCT00224549Phase 4
• Treatment of Supine Hypertension in Autonomic FailureCompletedNCT00223717Phase 1
• Olmesartan as an add-on to Amlodipine in HypertensionCompletedNCT00220233Phase 3
• Amlodipine as add-on to Olmesartan in HypertensionCompletedNCT00220220Phase 3
• Rationale and Design for Shiga Microalbuminuria Reduction TrialStatus unknownNCT00202618Phase 4
• Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive DrugsStatus unknownNCT00192803Phase 4
• Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular DiseaseCompletedNCT00190580Phase 4
• Treatment of Insulin Resistance in Hypertensive, Obese AdolescentsTerminatedNCT00185705Not applicable
• Olmesartan Medoxomil in AtherosclerosisCompletedNCT00185185Phase 3
• Olmesartan in Essential HypertensionCompletedNCT00185172Phase 3
• Olmesartan Medoxomil in Diabetes MellitusCompletedNCT00185159Phase 3
• Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe HypertensionCompletedNCT00185133Phase 3
• Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel BlockerCompletedNCT00185120Phase 4
• A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to InsulinCompletedNCT00185094Phase 4
• The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy SubjectsCompletedNCT00185055Phase 4
• Prophylactic Treatment of Episodic Cluster HeadacheCompletedNCT00184587Phase 2
• Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.CompletedNCT00180024Not applicable
• Hypertension and Cardiovascular Risk FactorsCompletedNCT00171782Phase 4
• Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.CompletedNCT00171756Phase 4
• Antialbuminuric Effects of Valsartan and LisinoprilTerminatedNCT00171600Phase 4
• Antiproteinuric Effect of Valsartan and LisinoprilCompletedNCT00171574Phase 4
• Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.CompletedNCT00171561Phase 4
• Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe HypertensionCompletedNCT00171535Phase 3
• A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood PressureCompletedNCT00171353Phase 4
• Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial DysfunctionCompletedNCT00171327Phase 4
• VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal WomenCompletedNCT00171132Phase 4
• A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+BenazeprilTerminatedNCT00171119Phase 4
• Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart FailureCompletedNCT00171106Phase 4
• A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and HypercholesterolemiaCompletedNCT00171093Phase 3
• VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term HemodialysisCompletedNCT00171080Phase 3
• VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With MicroalbuminuriaCompletedNCT00171067Phase 3
• A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of AgeCompletedNCT00171041Phase 3
• A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have HypertensionCompletedNCT00171028Phase 3
• VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan MedoxomilCompletedNCT00171015Phase 3
• Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine AloneCompletedNCT00171002Phase 3
• Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan AloneCompletedNCT00170989Phase 3
• A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With HypertensionCompletedNCT00170976Phase 3
• Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan AloneCompletedNCT00170963Phase 3
• A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic SyndromeCompletedNCT00170937Phase 4
• To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.CompletedNCT00170924Phase 4
• A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)CompletedNCT00168857Phase 4
• Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 HypertensionCompletedNCT00168779Phase 4
• Prevention of CHOP-induced Chronic CardiotoxicityCompletedNCT00162955Phase 4
• Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II DiabetesCompletedNCT00160160Not applicable
• Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary AldosteronismCompletedNCT00155064Phase 4
• Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.CompletedNCT00154024Not applicable
• INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic NephropathyCompletedNCT00153088Phase 4
• 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential HypertensionCompletedNCT00153049Phase 2
• 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt NephropathyCompletedNCT00153023Phase 4
• Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With HypercholesterolemiaWithdrawnNCT00152698Phase 3
• Effect of Losartan on Retinal Endothelial Function in Patients With Essential HypertensionWithdrawnNCT00152633Phase 2/3
• Olmesartan Medoxomil in Hypertension and Renal ImpairmentCompletedNCT00151827Phase 3
• Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mgCompletedNCT00146341Phase 3
• The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive SubjectsCompletedNCT00146289Phase 2
• Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan MonotherapyCompletedNCT00144222Phase 3
• A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 DiabetesStatus unknownNCT00144144Phase 4
• ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)CompletedNCT00140907Phase 4
• Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) StudyTerminatedNCT00140790Phase 4
• Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) TrialCompletedNCT00139386Phase 4
• Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive PatientsCompletedNCT00135551Phase 4
• OlmeSartan and Calcium Antagonists Randomized (OSCAR) StudyCompletedNCT00134160Phase 4
• A Morbidity-Mortality and Remodeling Study With ValsartanStatus unknownNCT00133328Phase 4
• A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate HypertensionCompletedNCT00133185Phase 3
• Candesartan in the Prevention of Relapsing Atrial FibrillationCompletedNCT00130975Phase 3
• Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose IntoleranceCompletedNCT00129233Phase 4
• Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive DeclineCompletedNCT00126516Phase 4
• Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)CompletedNCT00125645Phase 4
• Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive PatientsStatus unknownNCT00125463Phase 3
• Scandinavian Candesartan Acute Stroke Trial (SCAST)CompletedNCT00120003Phase 3
• Irbesartan in the Treatment of Hypertensive Patients With Metabolic SyndromeCompletedNCT00110422Phase 4
• Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)Status unknownNCT00108706Phase 4
• Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial FibrillationCompletedNCT00098137Phase 3
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate HypertensionCompletedNCT00095550Phase 3
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe HypertensionCompletedNCT00095394Phase 3
• Irbesartan Versus Placebo in Combination With Ramipril for Treatment of AlbuminuriaCompletedNCT00095290Phase 4
• Optimal Treatment for Kidney Disease in HIV Infected AdultsWithdrawnNCT00089518Phase 3
• Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed DoseCompletedNCT00034840Phase 4
• Study of Inherited Changes of Receptors Located on Blood VesselsCompletedNCT00001741Phase 1

← Angiotensin Receptor Antagonists overview